Source of Sarcopenia

{{Infobox concept | name = Sarcopenia | subtitle = Clinical practice | Defined by = Low muscle strength, confirmed by low muscle quantity | Assessed by = Grip strength, chair-stand time, gait speed | Not defined by = Muscle mass alone }} '''Sarcopenia''' is the loss of skeletal muscle accompanied by loss of strength or physical performance. Current consensus definitions place low muscle ''strength'' as the primary criterion, with low muscle quantity as confirmation — a deliberate reversal of earlier mass-based definitions.{{r|cruzjentoft2019}} The reordering matters for how the topic is discussed in the context of weight reduction. A fall in lean mass measured by [[Body composition assessment|body composition assessment]] is not sarcopenia; a fall in strength or function is the finding that would be.{{r|cruzjentoft2019}} Concern about sarcopenia during substantial pharmacological weight loss is reasonable in principle, particularly in older people and those with low muscle mass at baseline, and the evidence addressing it directly is limited.{{r|wilding2021}} == Definition and assessment == Consensus definitions require low muscle strength for a probable diagnosis, confirmed by low muscle quantity or quality, with poor physical performance indicating severity.{{r|cruzjentoft2019}} | Domain | Common measures | |---|---| | Strength | Grip strength; chair-stand time | | Quantity | Appendicular lean mass by DXA | | Performance | Gait speed; short physical performance battery | Grip strength is the most widely used screening measure because it is quick, cheap and correlates with strength elsewhere. Its cut-offs are population- and device-specific, as reference intervals generally are.{{r|cruzjentoft2019}} Sarcopenic obesity — low muscle with high fat mass — is a recognised phenotype and is harder to detect, since body weight does not signal it and the muscle deficit is concealed by adiposity.{{r|heymsfield2015}} == Relevance to weight reduction == All substantial weight loss reduces lean mass to some degree, and the compartment includes organ and water components as well as muscle. See [[Body composition assessment]].{{r|heymsfield2015}} The specific question — whether pharmacological weight loss reduces muscle disproportionately compared with equivalent loss by other means — is not answered by existing trials, which measured composition in subsets as a secondary outcome and compared against placebo arms losing little weight.{{r|wilding2021}} Resistance exercise and adequate protein intake are the interventions with evidence for attenuating lean-mass loss during caloric restriction generally. Extrapolating that evidence to pharmacological weight loss is reasonable and is an extrapolation.{{r|cruzjentoft2019}} == What would settle the question == A trial randomising to pharmacological or dietary weight loss matched for total weight change, with functional endpoints rather than composition alone, and adequate duration and power. No such trial has reported.{{r|wilding2021}} Until one does, the honest position is that lean-mass loss is documented, its functional consequence is not, and the difference between the two is the difference between a measurement and a clinical outcome. Nothing on this wiki is medical advice, and research-use compounds are not approved for human administration.{{r|ada2024}} == References == {{reflist}} <ref name="cruzjentoft2019">Cruz-Jentoft AJ, Bahat G, Bauer J, et al. "Sarcopenia: revised European consensus on definition and diagnosis." ''Age and Ageing'' 48(1):16–31 (2019). DOI:10.1093/ageing/afy169. PMID 30312372.</ref> <ref name="heymsfield2015">Heymsfield SB, Gonzalez MC, Shen W, Redman L, Thomas D. "Weight loss composition is one-fourth fat-free mass." ''Obesity Reviews'' 15(4):310–321 (2014). PMID 24447775.</ref> <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> == See also == * [[Body composition assessment]] * [[Lean mass preservation]] * [[Weight regain after discontinuation]] * [[Adverse effects of GLP-1 receptor agonists]] {{DEFAULTSORT:Sarcopenia}} [[Category:Nutrition and micronutrients]] [[Category:Body composition]] [[Category:Adverse effects]]